Compare Amphastar Pharmaceuticals Inc (AMPH) vs Goldman Sachs Group Inc (GS) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Goldman Sachs (GS) trades at $1,055.18, down 0.07% on the day, with a bullish technical outlook supported by moving averages and a neutral RSI. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $17.55 exceeding expectations. Revenue growth accelerated to $58.28 billion in 2025, and net income margin improved to 29.89%. Recent news highlights GS's role in leading high-profile IPOs, including Anthropic, signaling robust investment banking momentum.

The stock presents a favorable risk-reward profile with a consensus price target of $1,080, implying modest upside. Strengths include earnings momentum and leadership in M&A, but risks involve volatile cash flows and macroeconomic sensitivity. Analyst sentiment is mixed with 40% buy ratings, suggesting cautious optimism amid execution challenges.